Home
NewsNewsUnder the terms of the agreement, Exeltis will acquire exclusive rights to market and distribute Theranexus’ proprietary product across key regions, including the European Union, UK, Latin America, and selected Middle Eastern countries. This collaboration will target both Gaucher and Niemann-Pick type C diseases.
Salustiano Perez, CEO of Exeltis, adds: “We are thrilled to join forces with Theranexus and leverage our commercial capabilities to bring this much-needed therapy to patients globally. This partnership aligns with Exeltis’ mission to enhance patient care by broadening access to life-changing treatments.”
Julien Veys, Chief Business Officer at Theranexus, concludes: “We are delighted to build this alliance with the Exeltis team, addressing the needs of an underserved patient population. With an addressable market exceeding €200 million globally and a formulation tailored for a specific segment of rare disease patients, this partnership reflects our shared commitment to advancing therapeutic innovation and improving patient outcomes.
For the first time, the World Health Organization has officially listed the Ministry of Health, Labor, and Welfare/Pharmaceuticals and Medical Devices Agency (MHLW/PMDA) of Japan, Health Canada, and the Medicines and Healthcare Products Regulatory Agency (MHRA) of the UK as the new WHO-listed authorities (WLAs), a status that is granted to national authorities that meet the highest international regulatory benchmarks when it comes to medical products.
Fertility is a person’s ability to conceive children. In general, when a woman is unable to get pregnant even after at least one year of unprotected sex, she is considered to have infertility and her doctor will begin evaluating the possible causes.
Menopause can usher in a host of disruptive symptoms like hot flashes, night sweats and sleep problems. Hormone therapy promises relief. But many women wonder about taking it. That’s because the treatment, subject of a recent expert panel convened by the Food and Drug Administration, has long been shrouded in uncertainty.
With the partnership, PatientPoint’s waiting room and exam room screens will feature messaging that promotes MyHealthTeam’s platform, which serves over 27 million patients annually through an expanding network of more than 60 patient communities
In an age where customization is prized as well as friction is the enemy of efficiency, zero-click care – passive patient engagement by way of ambient sensing and IoT in hospitals
Explore the cost of IUI worldwide, comparing prices and factors aExplore the cost of IUI worldwide, comparing prices and factors aExplore the cost of IUI worldwide, comparing prices and factors a
